2020年青少年和年轻成人癌症统计
该研究分析了美国15-39岁青少年和年轻成人(AYA)按年龄组、性别和种族/民族划分的基于人群的癌症发病和死亡数据。2020年预计将有约89,500例新发癌症病例和9,270例癌症死亡。总体癌症发病率在最近十年(2007-2016)所有AYA年龄组均上升,主要由甲状腺癌驱动;总体癌症死亡率在2008-2017年间除30-39岁女性外每年下降1%。
要点
- 2020年美国15-39岁AYA预计新发癌症89,500例,死亡9,270例。
- 2007-2016年AYA总体癌症发病率上升,甲状腺癌每年约增3%-4%。
- 2008-2017年AYA总体癌症死亡率每年下降1%,但30-39岁女性因乳腺癌下降趋缓而稳定。
核心结论
- AYA癌症发病总体上升而死亡率总体下降,但存在年龄和性别异质性。
- 30-39岁女性死亡率稳定,结直肠癌和子宫体癌发病率在该年龄组上升。
研究设计与样本
- 基于美国人群的癌症发病和死亡数据分析,按年龄组(15-19、20-29、30-39岁)、性别和种族/民族分层。
主要发现
- 2020年预计新发癌症89,500例,癌症死亡9,270例。
- 2007-2016年所有AYA年龄组总体癌症发病率上升,甲状腺癌在20-39岁每年约增3%,15-19岁每年增4%。
- 肥胖相关癌症发病率在多数年龄组上升:肾癌所有年龄组每年增3%,子宫体癌20-39岁每年增3%,结直肠癌20-39岁每年增0.9%-1.5%。
- 15-29岁黑色素瘤发病率每年下降4%-6%,30-39岁稳定。
- 2008-2017年总体癌症死亡率除30-39岁女性外每年下降1%;30-39岁女性因乳腺癌下降趋缓而稳定。
临床怎么用
- 临床医生应提高对AYA癌症早期症状和体征的警觉性。
- 需关注30-39岁女性乳腺癌死亡率下降趋缓及结直肠癌、子宫体癌发病和死亡率上升趋势。
- 应促进AYA患者临床试验入组和公平医疗可及性。
局限性
- 数据为基于人群的统计,未涉及个体水平风险因素。
- 生存率差异反映组织学亚型分布和治疗差异,但未深入分析原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer statistics for adolescents and young adults (AYAs) (aged 15-39 years) are often presented in aggregate, masking important heterogeneity. The authors analyzed population-based cancer incidence and mortality for AYAs in the United States by age group (ages 15-19, 20-29, and 30-39 years), sex, and race/ethnicity. In 2020, there will be approximately 89,500 new cancer cases and 9270 cancer deaths in AYAs. Overall cancer incidence increased in all AYA age groups during the most recent decade (2007-2016), largely driven by thyroid cancer, which rose by approximately 3% annually among those aged 20 to 39 years and 4% among those aged 15 to 19 years. Incidence also increased in most age groups for several cancers linked to obesity, including kidney (3% annually across all age groups), uterine corpus (3% in the group aged 20-39 years), and colorectum (0.9%-1.5% in the group aged 20-39 years). Rates declined dramatically for melanoma in the group aged 15 to 29 years (4%-6% annually) but remained stable among those aged 30 to 39 years. Overall cancer mortality declined during 2008 through 2017 by 1% annually across age and sex groups, except for women aged 30 to 39 years, among whom rates were stable because of a flattening of declines in female breast cancer. Rates increased for cancers of the colorectum and uterine corpus in the group aged 30 to 39 years, mirroring incidence trends. Five-year relative survival in AYAs is similar across age groups for all cancers combined (range, 83%-86%) but varies widely for some cancers, such as acute lymphocytic leukemia (74% in the group aged 15-19 years vs 51% in the group aged 30-39 years) and brain tumors (77% vs 66%), reflecting differences in histologic subtype distribution and treatment. Progress in reducing cancer morbidity and mortality among AYAs could be addressed through more equitable access to health care, increasing clinical trial enrollment, expanding research, and greater alertness among clinicians and patients for early symptoms and signs of cancer. Further progress could be accelerated with increased disaggregation by age in research on surveillance, etiology, basic biology, and survivorship.
引用
- Miller KD, Fidler-Benaoudia M, Keegan TH, et al. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 2020. PMID: 32940362. doi:10.3322/caac.21637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。